Group 1 - The core point of the news is that Jingxin Pharmaceutical experienced a 5.02% decline in stock price, reaching 17.99 yuan per share, with a trading volume of 168 million yuan and a turnover rate of 1.27%, resulting in a total market capitalization of 15.49 billion yuan [1] - Jingxin Pharmaceutical, established on February 13, 1999, and listed on July 15, 2004, is located in Zhejiang Province and specializes in the research, production, and sales of chemical preparations, traditional Chinese medicine, biological preparations, chemical raw materials, and medical devices [1] - The company's main business revenue composition is 82.46% from pharmaceutical manufacturing and 17.54% from medical devices [1] Group 2 - According to data from the top ten holdings of funds, Hongtu Innovation Fund has a significant position in Jingxin Pharmaceutical, with its Hongtu Innovation Steady Mixed A Fund (006700) increasing its holdings by 68,000 shares in the second quarter, totaling 395,700 shares, which accounts for 2.95% of the fund's net value, ranking as the fifth-largest holding [2] - The Hongtu Innovation Steady Mixed A Fund was established on March 13, 2019, with a current scale of 748.024 million yuan, yielding 1.95% this year, ranking 7530 out of 8159 in its category, and a one-year return of 2.6%, ranking 7326 out of 8030 [2] - The estimated floating loss for the fund today is approximately 375,900 yuan [2]

Group 1 - The core point of the news is that Jingxin Pharmaceutical experienced a stock price increase of 5.39% on September 30, reaching 20.72 CNY per share, with a trading volume of 233 million CNY and a turnover rate of 1.59%, resulting in a total market capitalization of 17.841 billion CNY [1] - Jingxin Pharmaceutical, established on February 13, 1999, and listed on July 15, 2004, is located in Zhejiang Province and specializes in the research, production, and sales of chemical preparations, traditional Chinese medicine, biological preparations, chemical raw materials, and medical devices [1] - The company's main business revenue composition is 82.46% from pharmaceutical manufacturing and 17.54% from medical devices [1] Group 2 - Red Soil Innovation Fund has a significant holding in Jingxin Pharmaceutical, with its fund "Red Soil Innovation Steady Mixed A" (006700) increasing its stake by 68,000 shares in the second quarter, bringing the total to 395,700 shares, which accounts for 2.95% of the fund's net value, making it the fifth-largest holding [2] - The fund "Red Soil Innovation Steady Mixed A" was established on March 13, 2019, with a latest scale of 74.8024 million CNY, achieving a year-to-date return of 1.64% and a one-year return of 2.86% [2] - The fund has a cumulative return of 59.19% since its inception [2]